Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Fulton Medicinali S P A currently has 2 pending office actions in the Semiconductors, Circuits & Optics technology area. These actions are assigned to 2 distinct examiners. The prosecution is occurring across 2 distinct art units, which indicates that the company's filings are being reviewed by different specialized groups within the patent office.
The busiest examiner for this portfolio is YOUNG, MONICA S, who is responsible for 1 pending office action. This 1 pending action is equal to the workload of the other of the 2 distinct examiners. Because the 2 pending office actions are split between 2 distinct examiners and 2 distinct art units, the company is engaging with different officials in different technical contexts.
Practitioners should note that the Semiconductors, Circuits & Optics filings are being reviewed by 2 distinct examiners, providing different points of contact for the 2 pending office actions. The 2 distinct art units suggest a lack of concentration in a single technical group. YOUNG, MONICA S manages 1 pending action, showing that no single examiner dominates the current portfolio. This distribution defines the current prosecution landscape for Fulton Medicinali S P A.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YOUNG, MONICA S | 1 | 74.6% | +32.6% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18424503 | INDOMETHACIN PHARMACEUTICAL COMPOSITION | YOUNG, MONICA S | 20d |
| 17869346 | INDOMETHACIN PHARMACEUTICAL COMPOSITION | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 2855 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18424503 | INDOMETHACIN PHARMACEUTICAL COMPOSITION | YOUNG, MONICA S | 2855 | §103 | Final Rejection | 20d | Pending | Jan 26, 2024 |
| 17869346 | INDOMETHACIN PHARMACEUTICAL COMPOSITION | LEE, WILLIAM Y | 1623 | §103 | Non-Final OA | — | Pending | Jul 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial